{
    "relation": [
        [
            "",
            "IL-2",
            "Control"
        ],
        [
            "Description",
            "Consenting patients who were assigned IL-2 during the main phase of the study, including patients who took IL-2 alone as well as patients who took IL-2 with ART.",
            "Consenting patients who were in the control group during the main phase of the trial."
        ]
    ],
    "pageTitle": "Effect of Intermittent Aldesleukin Treatment With or Without Anti-HIV Drugs in HIV Infected People - Study Results - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/results/NCT00110812?sect=Xk0156&view=results",
    "hasHeader": true,
    "headerPosition": "MIXED",
    "tableType": "RELATION",
    "tableNum": 25,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042989826.86/warc/CC-MAIN-20150728002309-00339-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 860908471,
    "recordOffset": 860892534,
    "tableOrientation": "HORIZONTAL",
    "textBeforeTable": "Reporting Groups No text entered. Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details Participants were enrolled by HIV care providers between December 2005 and June 2008. When the main study ended in February 2009, patients who consented to a study extension were followed another 2 years, during which study drug was not given. Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations Recruitment Details \u00a0 Hide Participant Flow \u00a0 Participant Flow Drug: IL-2 Intervention: HIV Infections Condition: Allocation:\u00a0Randomized; \u00a0 Endpoint\u00a0Classification:\u00a0Safety/Efficacy\u00a0Study; \u00a0 Intervention\u00a0Model:\u00a0Parallel\u00a0Assignment; \u00a0 Masking:\u00a0Open\u00a0Label; \u00a0 Primary\u00a0Purpose:\u00a0Treatment Study Design: Interventional Study",
    "textAfterTable": "IL-2 With Pericycle HAART During the main study, participants will receive aldesleukin under the skin twice daily for 5 consecutive days every 8 weeks for 3 cycles, then as needed to maintain CD4 counts at or above a goal level; in addition, this group will also take HAART for 3 days prior to the start of each aldesleukin cycle, throughout the 5-day aldesleukin cycle, and for 2 days after the end of each aldesleukin cycle (for a maximum of 10 days with each aldesleukin cycle). Patients did not receive aldesleukin during the extension phase. Participant Flow for 2 periods Period 1: \u00a0 Main Study \u00a0 \u00a0 No IL-2 \u00a0 \u00a0 IL-2 Without ART \u00a0 \u00a0 IL-2 With Pericycle HAART \u00a0 STARTED \u00a0 \u00a0 91 \u00a0 \u00a0 89 \u00a0 \u00a0 87 \u00a0 COMPLETED \u00a0 \u00a0 83 \u00a0 \u00a0 78 \u00a0 \u00a0 74 \u00a0",
    "hasKeyColumn": false,
    "keyColumnIndex": -1,
    "headerRowIndex": 0
}